½ÃÀ庸°í¼­
»óǰÄÚµå
1552969

³ì³»Àå Áúȯ ¸ðµ¨(2024³â)

2024 Glaucoma Disease Model

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Market Scope, LLC | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è ³ì³»Àå ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ³ì³»Àå À¯Çüº° ¹× ¿¬·É´ëº° ±¹°¡º° À¯º´·ü µ¥ÀÌÅÍ µîÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

  • Æó¼â ¿ì°¢ ³ì³»Àå
  • °³¹æ°¢ ³ì³»Àå
  • ¿¬¹ß¼º ³ì³»Àå
  • °í¾È¾ÐÁõ
LSH 24.09.20

Market Scope's "2024 Glaucoma Disease Model" offers extensive country-level prevalence data and five-year forecasts for glaucoma by type and by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients' diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

Methodology:

Market Scope utilizes proprietary demographics models and the latest clinical research to arrive at the diseased populations by country. The glaucoma disease model considers over 100 clinical studies and carefully evaluates each study input based on the age, sample size, and scope of the study.

Contents:

The "2024 Glaucoma Disease Model" provides country-level prevalence data by age group for the 228 countries with a population over a million for the following conditions:

  • Angle-closure glaucoma
  • Open-angle glaucoma
  • Secondary glaucoma
  • Ocular hypertension
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦